CNSide® Diagnostic May Cut Leptomeningeal Metastases Healthcare Costs by 40%, Boosting Commercialization Prospects
PSTV sits 49% above its 52-week low of $0.163.
Summary
Plus Therapeutics announced that new health economics analysis for its CNSide® cerebrospinal fluid (CSF) assay will be presented at the ISPOR 2026 Annual Meeting. The analysis suggests that earlier detection and therapeutic management of leptomeningeal metastases (LM) using CNSide® may reduce overall LM-related healthcare costs by approximately 40%. This positive product development comes shortly after the company reported a significant net loss for 2025, raising substantial doubt about its ability to continue as a going concern and facing Nasdaq delisting risk. The potential for a 40% cost reduction is a strong economic argument for CNSide®'s adoption by payers and health systems, which is crucial for the product's commercialization in the U.S. This provides a much-needed positive catalyst for a company facing severe financial headwinds. Investors will be watching for the full presentation at ISPOR in May and subsequent updates on CNSide®'s commercialization progress and market adoption.
At the time of this announcement, PSTV was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.5M. The 52-week trading range was $0.16 to $2.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.